CellaVision (part of Sysmex)

Lund, Sweden  All Sweden companies → — Founded 1994
Healthcare Conglomerate Medical Device / Hardware Point-of-Care Diagnostics
Lab & Diagnostics Pathology AI
Public Company — $12.5M
Website Claim this company

Products

CellaVision DM Series
CellaVision (part of Sysmex)
Lab & Diagnostics
CellaVision DM Series are AI-powered digital morphology systems that automate and standardize the review of blood and body fluid smears, assisting in the classification of cells for hematology diagnostics. They leverage artificial intelligence, deep learning, and digital imaging to standardize and simplify manual cell morphology analysis.
Contact vendor for pricing

See all 1 product →

About CellaVision (part of Sysmex)

CellaVision is a global leader in digital hematology microscopy solutions, dedicated to transforming and optimizing workflows in clinical laboratories of all sizes. The company leverages advanced digital imaging, artificial intelligence (AI), and deep learning to automate and standardize the manual analysis of blood and other body fluid cells. This innovative approach significantly enhances diagnostic accuracy and efficiency by providing high-quality digital images for review and pre-classification by medical morphologists.

Their comprehensive product portfolio includes analyzers, instruments, reagents, and sophisticated software designed for various applications, such as differential white blood cell counts, advanced red blood cell morphology analysis, and examination of body fluid smears. By streamlining labor-intensive processes, CellaVision’s technology assists healthcare professionals in the rapid and precise diagnosis and monitoring of a wide range of diseases, including infections and cancers. The company is also actively engaged in research and development, exploring next-generation cell morphology analyzers, including those incorporating Fourier Ptychographic Microscopy (FPM) and applications for bone marrow analysis, to further expand diagnostic capabilities beyond traditional hematology.

What Physicians Need to Know

Digital Cell Morphology Automation
CellaVision specializes in automating and streamlining the process of performing blood and body fluid cell differentials, replacing traditional manual microscopy. Their systems digitally capture, pre-classify, and present cells for review by medical technologists.
AI-Assisted Cell Classification
The company leverages innovative image analysis technology and artificial neural networks to perform pre-classification of white blood cells (WBCs) into multiple cell types (e.g., 17 types) and pre-characterization of red blood cell (RBC) morphology (e.g., 21 characteristics).
Enhanced Workflow Efficiency
CellaVision's technology significantly reduces sample review time, often by up to 50%, and enables laboratories to handle a greater volume of samples, making more efficient use of skilled staff.
Standardization and Quality Improvement
By automating cell location and pre-classification, the systems reduce the subjectivity of cell identification, promote consistency, and improve the overall quality and reliability of differential results.
Remote Review and Collaboration
Cell images are stored in a centralized database, allowing for remote access, review, and reporting from various locations within a network, facilitating collaboration among medical technologists, supervisors, and pathologists.
Integrated Hematology Solutions
CellaVision's systems are designed to integrate seamlessly with Sysmex hematology analyzers, automating the entire process from slide preparation to cell morphology analysis, which is a key differentiator in the market.
Physician Tip

For physicians, CellaVision's AI tools mean faster, more standardized, and reliable blood and body fluid differential results, which can aid in quicker and more accurate disease diagnoses, especially for infections and serious conditions like cancer. The digital nature of the results allows for easy access to patient's cell images and historical data, supporting long-term case management and facilitating remote consultations with morphology experts. This leads to improved diagnostic certainty and more efficient clinical decision-making. While the system provides highly accurate pre-classification, critical blood film abnormalities still benefit from oversight by skilled laboratory staff.

CellaVision has a long-standing and deep strategic alliance with Sysmex Corporation, integrating their digital cell morphology technology with Sysmex's hematology platforms (e.g., Sysmex XN-series, DI-60 Automated Digital Cell Morphology Analyzer). This integration allows for a highly automated workflow, from cell counting and slide preparation to digital morphology analysis. The systems also support bi-directional LIS (Laboratory Information System) communication via ASTM and Ethernet, enabling seamless data transfer and patient information management.

Products by CellaVision (part of Sysmex)

1 product in the directory

CellaVision DM Series
CellaVision (part of Sysmex)
Lab & Diagnostics
CellaVision DM Series are AI-powered digital morphology systems that automate and standardize the review of blood and body fluid smears, assisting in the classification of cells for hematology diagnostics. They leverage artificial intelligence, deep learning, and digital imaging to standardize and simplify manual cell morphology analysis.
Contact vendor for pricing

What the Web Says

CellaVision, a part of Sysmex, offers automated digital cell morphology analyzers that are generally well-regarded for improving efficiency and standardization in hematology labs, particularly in high-volume settings. While the technology is praised for saving time on routine cases and facilitating remote review and collaboration, some users note limitations in its ability to accurately identify certain cell morphologies and handle specific types of samples, often requiring manual verification. Employer reviews for Sysmex indicate a generally positive culture and work environment, though some concerns exist regarding pay and opportunities for advancement.

Overall: Mixed

Strengths

  • Increases efficiency and saves time on routine differential counts.
  • Facilitates remote review and collaboration among lab professionals.
  • Reduces staff eye fatigue and physical strain from manual microscopy.
  • Provides consistent cell classification and on-line reference images for training.
  • Good for high-throughput laboratories.
  • Positive company culture and supportive colleagues at Sysmex.

Limitations

  • Limitations in accurately identifying certain abnormal morphologies and inclusions.
  • Can be slower for stat cases compared to manual methods.
  • Challenges with body fluid analysis, especially low WBC counts.
  • Color distortions and image quality issues compared to direct microscopy.
  • Not always necessary or cost-effective for very small labs with low diff volumes.
  • Some Sysmex employees report lower-than-market pay and limited advancement opportunities.

Based on reviews from: Reddit (r/medlabprofessionals), Indeed.com, The Pathology Blog, InPractise, American Journal of Clinical Pathology (Oxford Academic), PMC - NIH (National Institutes of Health)

Last updated: 2026-08-10

Videos

News, demos, and interviews about CellaVision (part of Sysmex).

Loading videos...

Videos load interactively. If none appear, search YouTube for CellaVision (part of Sysmex) →

View all on YouTube

Press & Coverage

CellaVision
CellaVision and Sysmex Sign Strategic Alliance Agreement
CellaVision and Sysmex Corporation have signed a Strategic Alliance Agreement to strengthen their joint leadership in hematology and explore new diagnostic opportunities, extending their partnership until 2038. This collaboration aims to streamline laboratory processes and advance digital cell morphology through deeper innovation and commercialization.
2024-02
Sysmex Europe SE
Sysmex and CellaVision expand alliance with a view to advancing hematology solutions
Sysmex Corporation and CellaVision AB are expanding their alliance to advance hematology solutions, including next-generation cell morphology analyzers, with an agreement extended until 2038. This collaboration leverages Sysmex's expertise in workflow efficiency and CellaVision's digital imaging and analysis technologies to enhance diagnostic support.
2024-03
Taylor & Francis
Correlation of Sysmex-XN9000 and CellaVision Advanced RBC software on anisocytosis
This study evaluated the consistency of erythrocyte volume heterogeneity parameters between the Sysmex-XN9000 automated analyzer and the CellaVision-DI60 advanced red blood cell software using 500 blood samples. The research concluded that all parameters of heterogeneity degree show good accuracy and consistency across both instruments.
2023-08
PMC - NIH
A critical analysis of CellaVision systems in the modern hematology laboratory
A literature review found that CellaVision systems accurately characterize cellular morphology, especially for neutrophils, lymphocytes, and common red blood cell changes. However, challenges remain in detecting specific findings like immature granulocytes and red blood cell agglutination.
2025-05
PR Newswire
Sysmex America to Distribute FDA Cleared CellaVisionu00ae DC-1 for Low-Volume Hematology Labs
Sysmex America, Inc. announced it would distribute the CellaVisionu00ae DC-1, which received FDA 510(k) clearance on October 16, 2020, for low-volume hematology labs in the US and Canada. The CellaVision DC-1 automates and simplifies blood cell differentials, improving efficiency and quality.
2020-11
CAP TODAY
Sysmex adds FDA-cleared CellaVision DC-1 to portfolio
Sysmex America has integrated the FDA 510(k)-cleared CellaVision DC-1 into its product line for low-volume hematology laboratories. This analyzer streamlines blood cell differential processes by automating cell location and preclassification, enhancing efficiency and standardization.
2020-11
PubMed
Evaluation of the detection of blasts by Sysmex hematology instruments, CellaVision DM96, and manual microscopy using flow cytometry as the confirmatory method
This study evaluated the diagnostic ability of blast flags from Sysmex instruments (XE/XN), manual microscopy, and CellaVision DM96 against flow cytometry. The CellaVision reclassification procedure showed diagnostic ability for predicting blasts comparable to manual microscopy.
2019-02
ASM Journals
Detection of Intracellular Parasites by Use of the CellaVision DM96 Analyzer during Routine Screening of Peripheral Blood Smears
A study comparing the CellaVision DM96 analyzer with routine microscopy for detecting Plasmodium and Babesia species in peripheral blood smears found that CellaVision detected 73% of positive samples, while microscopy detected 81%. Pathologist review of CellaVision images increased its detection rate to 85%.
2014-12

Frequently Asked Questions

CellaVision provides digital hematology microscopy solutions, including analyzers like the CellaVision DM1200, DM9600, and DC-1, along with specialized software applications. These systems leverage AI for tasks such as the pre-classification of white blood cells and pre-characterization of red blood cell morphologies, aiming to automate and streamline laboratory workflows.
CellaVision's AI algorithms are developed through extensive training and rigorous validation processes using large sets of diverse samples. While the AI performs pre-classification, human review by a morphologist is still a crucial step for verification and reclassification if needed, ensuring diagnostic certainty. The AI does not adapt or 'learn in the lab' post-deployment to maintain consistent and guaranteed results.
Sysmex America, which distributes CellaVision products, manages FDA registrations and Health Canada licenses, ensuring compliance with federal and state regulations, including HIPAA. CellaVision also declares compliance with European regulations such as IVDR (EU) 2017/746, the Machinery Directive 2006/42/EC, and the ROHS Directive 2011/65/EU for its devices. Their quality management systems adhere to standards like ISO 13485 and ISO 14971.
Specific pricing models for CellaVision's AI-enabled systems are generally not publicly disclosed, as they can vary based on configuration, regional agreements, and integrated solutions. However, a list price of approximately $37,465.00 to $45,000 has been cited for the CellaVision DC-1 Digital Morphology Analyzer. For detailed pricing, it is recommended to contact CellaVision or Sysmex directly.
CellaVision provides comprehensive customer support, including technical assistance, application guidance, and training through its Customer Support Team. They offer an 'Ask the Expert' webinar series and certification programs for both service engineers and application specialists via the CellaVision Academy. Remote review software also facilitates off-site collaboration and consultation.
CellaVision and Sysmex have a long-standing strategic alliance, initiated over 20 years ago, which has been extended until 2038. This partnership involves joint product development, such as the Sysmex DI-60, and leverages Sysmex's hematology expertise with CellaVision's digital imaging and AI technologies. This collaboration ensures integrated solutions, streamlined workflows, and a stable framework for ongoing innovation and global market reach.
CellaVision systems are designed to integrate into existing hematology workflows, often connecting with Sysmex hematology analyzers and capable of sharing databases with other CellaVision DM and Sysmex DI-60 analyzers. They support bi-directional interface communication with Laboratory Information Systems (LIS) to query patient demographics and order data, and to streamline the reporting of results, thereby reducing transcription errors and enhancing efficiency.

Related Companies

CAIMed (Niedersächsisches Zentrum für KI und Kausale Methoden in der Medizin)
Hannover, Germany (Lower Saxony region)

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm
Berkeley, United States and London, United Kingdom. European office in Barcelona, Spain and Gothenburg, Sweden.

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA
London, UK

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Fraunhofer-Gesellschaft (Fraunhofer AICOS) / PALMX APPS LTD / Skin Analytics
London, United Kingdom

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI
Canberra, ACT, Australia

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART
Boizenburg / Elbe, Germany

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]
Suggest an Edit →
AI Tool Finder
AI-powered search. Results may not be comprehensive.